BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Follicular Lymphoma readouts · AssetMemo
X-WR-CALDESC:Upcoming phase 1/2 and later readouts in Follicular Lymphoma\,
  from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT03980171-2649@assetmemo.bio
DTSTAMP:20261121T005642Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Obinutuzumab: Phase 1/2 readout est. (NCT03980171)
DESCRIPTION:Obinutuzumab\, phase 1/2\, Follicular Lymphoma.\nStudy: Study o
 f Lenalidomide\, Venetoclax and Obinutuzumab in Patients With Treatment-Na
 ïve Follicular Lymphoma\nEstimated primary completion: November 2026. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/obinutuzumab#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT03980171
URL:https://assetmemo.bio/drug/obinutuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03980171-3126@assetmemo.bio
DTSTAMP:20261121T005642Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Lenalidomide: Phase 1/2 readout est. (NCT03980171)
DESCRIPTION:Lenalidomide\, phase 1/2\, Follicular Lymphoma.\nStudy: Study o
 f Lenalidomide\, Venetoclax and Obinutuzumab in Patients With Treatment-Na
 ïve Follicular Lymphoma\nEstimated primary completion: November 2026. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/lenalidomide#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT03980171
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02393157-2649@assetmemo.bio
DTSTAMP:20261121T005642Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Obinutuzumab: Phase 2 readout est. (NCT02393157)
DESCRIPTION:Obinutuzumab\, phase 2\, Follicular Lymphoma.\nStudy: Obinutuzu
 mab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHL\nEstimat
 ed primary completion: December 2026. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/obinutuzumab#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT02393157
URL:https://assetmemo.bio/drug/obinutuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06549335-2649@assetmemo.bio
DTSTAMP:20261121T005642Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Obinutuzumab: Phase 2 readout est. (NCT06549335)
DESCRIPTION:Obinutuzumab\, phase 2\, Follicular Lymphoma.\nStudy: Zanubruti
 nib\, Obinutuzumab and Lenalidomide (ZGR) in High-risk Treatment-naive Pat
 ients with Follicular Lymphoma (FL)\nEstimated primary completion: 1 Decem
 ber 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/obinutuzuma
 b#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06
 549335
URL:https://assetmemo.bio/drug/obinutuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06549335-3126@assetmemo.bio
DTSTAMP:20261121T005642Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Lenalidomide: Phase 2 readout est. (NCT06549335)
DESCRIPTION:Lenalidomide\, phase 2\, Follicular Lymphoma.\nStudy: Zanubruti
 nib\, Obinutuzumab and Lenalidomide (ZGR) in High-risk Treatment-naive Pat
 ients with Follicular Lymphoma (FL)\nEstimated primary completion: 1 Decem
 ber 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/lenalidomid
 e#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06
 549335
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06549335-10908@assetmemo.bio
DTSTAMP:20261121T005642Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Brukinsa (zanubrutinib): Phase 2 readout est. (NCT06549335)
DESCRIPTION:Brukinsa (zanubrutinib)\, phase 2\, Follicular Lymphoma.\nStudy
 : Zanubrutinib\, Obinutuzumab and Lenalidomide (ZGR) in High-risk Treatmen
 t-naive Patients with Follicular Lymphoma (FL)\nEstimated primary completi
 on: 1 December 2026. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 zanubrutinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT06549335
URL:https://assetmemo.bio/drug/zanubrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06471738-4915@assetmemo.bio
DTSTAMP:20261121T005642Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Rituxan (Rituximab): Phase 2 readout est. (NCT06471738)
DESCRIPTION:Rituxan (Rituximab)\, phase 2\, Follicular Lymphoma.\nStudy: Co
 mbination of Zanubrutinib\, Rituximab and Venetoclax in Patients With Prev
 iously Untreated Follicular Lymphoma\nEstimated primary completion: 30 Dec
 ember 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/rituximab
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT064
 71738
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06471738-10908@assetmemo.bio
DTSTAMP:20261121T005642Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Brukinsa (zanubrutinib): Phase 2 readout est. (NCT06471738)
DESCRIPTION:Brukinsa (zanubrutinib)\, phase 2\, Follicular Lymphoma.\nStudy
 : Combination of Zanubrutinib\, Rituximab and Venetoclax in Patients With 
 Previously Untreated Follicular Lymphoma\nEstimated primary completion: 30
  December 2026. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/zanub
 rutinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT06471738
URL:https://assetmemo.bio/drug/zanubrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07128641-5820@assetmemo.bio
DTSTAMP:20261121T005642Z
DTSTART;VALUE=DATE:20270102
DTEND;VALUE=DATE:20270103
SUMMARY:Odronextamab: Phase 2 readout est. (NCT07128641)
DESCRIPTION:Odronextamab\, phase 2\, Follicular Lymphoma.\nStudy: Odronexta
 mab in Low Tumor Volume Advanced FL\nEstimated primary completion: 2 Janua
 ry 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/odronextamab
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT071
 28641
URL:https://assetmemo.bio/drug/odronextamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05451810-10986@assetmemo.bio
DTSTAMP:20261121T005642Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Epcoritamab: Phase 2 readout est. (NCT05451810)
DESCRIPTION:Epcoritamab\, phase 2\, Diffuse Large B-Cell Lymphoma.\nStudy: 
 A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Admini
 stered in the Outpatient Setting in Adult Participants With Relapsed or Re
 fractory Diffuse Large B-Cell Lymphoma and Classic Follicular Lymphoma\nEs
 timated primary completion: March 2027. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/epcoritamab#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT05451810
URL:https://assetmemo.bio/drug/epcoritamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04799275-4915@assetmemo.bio
DTSTAMP:20261121T005642Z
DTSTART;VALUE=DATE:20270301
DTEND;VALUE=DATE:20270302
SUMMARY:Rituxan (Rituximab): Phase 2/3 readout est. (NCT04799275)
DESCRIPTION:Rituxan (Rituximab)\, phase 2/3\, Diffuse Large B-Cell Lymphoma
 .\nStudy: Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy
  in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell L
 ymphoma\nEstimated primary completion: 1 March 2027. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/rituximab#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT04799275
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04450173-2649@assetmemo.bio
DTSTAMP:20261121T005642Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Obinutuzumab: Phase 2 readout est. (NCT04450173)
DESCRIPTION:Obinutuzumab\, phase 2\, Follicular Lymphoma.\nStudy: Obinutuzu
 mab\, Ibrutinib\, and Venetoclax for the Treatment of Previously Untreated
  Stage II-IV Follicular Lymphoma\nEstimated primary completion: April 2027
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/obinutuzumab#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT04450173
URL:https://assetmemo.bio/drug/obinutuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06510361-10986@assetmemo.bio
DTSTAMP:20261121T005642Z
DTSTART;VALUE=DATE:20270501
DTEND;VALUE=DATE:20270502
SUMMARY:Epcoritamab: Phase 2 readout est. (NCT06510361)
DESCRIPTION:Epcoritamab\, phase 2\, Follicular Lymphoma.\nStudy: A Phase 2 
 Study of Epcoritamab in Patients With Follicular Lymphoma and Marginal Zon
 e Lymphoma Not Accomplishing a Complete Response With Upfront Therapy\nEst
 imated primary completion: 1 May 2027. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/epcoritamab#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT06510361
URL:https://assetmemo.bio/drug/epcoritamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT01473628-4915@assetmemo.bio
DTSTAMP:20261121T005642Z
DTSTART;VALUE=DATE:20270520
DTEND;VALUE=DATE:20270521
SUMMARY:Rituxan (Rituximab): Phase 1/2 readout est. (NCT01473628)
DESCRIPTION:Rituxan (Rituximab)\, phase 1/2\, Follicular Lymphoma.\nStudy: 
 Radiation Therapy and Rituximab in Treating Patients With Stage I-II Grade
  1 or Grade 2 Follicular Lymphoma\nEstimated primary completion: 20 May 20
 27. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/rituximab#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT01473628
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06834373-4915@assetmemo.bio
DTSTAMP:20261121T005642Z
DTSTART;VALUE=DATE:20270610
DTEND;VALUE=DATE:20270611
SUMMARY:Rituxan (Rituximab): Phase 2 readout est. (NCT06834373)
DESCRIPTION:Rituxan (Rituximab)\, phase 2\, Diffuse Large B-Cell Lymphoma.\
 nStudy: Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refr
 actory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell Therapy\nE
 stimated primary completion: 10 June 2027. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/rituximab#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT06834373
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06959732-2649@assetmemo.bio
DTSTAMP:20261121T005642Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Obinutuzumab: Phase 2 readout est. (NCT06959732)
DESCRIPTION:Obinutuzumab\, phase 2\, Follicular Lymphoma.\nStudy: Zanubruti
 nib Combined With G-CVP in Previously Untreated FL\nEstimated primary comp
 letion: 30 June 2027. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /obinutuzumab#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT06959732
URL:https://assetmemo.bio/drug/obinutuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06959732-10908@assetmemo.bio
DTSTAMP:20261121T005642Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Brukinsa (zanubrutinib): Phase 2 readout est. (NCT06959732)
DESCRIPTION:Brukinsa (zanubrutinib)\, phase 2\, Follicular Lymphoma.\nStudy
 : Zanubrutinib Combined With G-CVP in Previously Untreated FL\nEstimated p
 rimary completion: 30 June 2027. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/zanubrutinib#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT06959732
URL:https://assetmemo.bio/drug/zanubrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04998669-4915@assetmemo.bio
DTSTAMP:20261121T005642Z
DTSTART;VALUE=DATE:20270801
DTEND;VALUE=DATE:20270802
SUMMARY:Rituxan (Rituximab): Phase 2 readout est. (NCT04998669)
DESCRIPTION:Rituxan (Rituximab)\, phase 2\, Follicular Lymphoma.\nStudy: Lo
 ncastuximab Tesirine in Combination With Rituximab in Patients With Relaps
 ed or Refractory Follicular Lymphoma\nEstimated primary completion: 1 Augu
 st 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/rituximab#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT049986
 69
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06112847-3126@assetmemo.bio
DTSTAMP:20261121T005642Z
DTSTART;VALUE=DATE:20270810
DTEND;VALUE=DATE:20270811
SUMMARY:Lenalidomide: Phase 2 readout est. (NCT06112847)
DESCRIPTION:Lenalidomide\, phase 2\, Follicular Lymphoma.\nStudy: Lenalidom
 ide and Epcoritamab for the Treatment of Previously Untreated Follicular L
 ymphoma\nEstimated primary completion: 10 August 2027. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/lenalidomide#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT06112847
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06112847-10986@assetmemo.bio
DTSTAMP:20261121T005642Z
DTSTART;VALUE=DATE:20270810
DTEND;VALUE=DATE:20270811
SUMMARY:Epcoritamab: Phase 2 readout est. (NCT06112847)
DESCRIPTION:Epcoritamab\, phase 2\, Follicular Lymphoma.\nStudy: Lenalidomi
 de and Epcoritamab for the Treatment of Previously Untreated Follicular Ly
 mphoma\nEstimated primary completion: 10 August 2027. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/epcoritamab#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT06112847
URL:https://assetmemo.bio/drug/epcoritamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06536049-10986@assetmemo.bio
DTSTAMP:20261121T005642Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Epcoritamab: Phase 1/2 readout est. (NCT06536049)
DESCRIPTION:Epcoritamab\, phase 1/2\, Diffuse Large B-Cell Lymphoma.\nStudy
 : Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory A
 ggressive B-Cell Non-Hodgkin Lymphoma\nEstimated primary completion: 31 Au
 gust 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/epcoritama
 b#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06
 536049
URL:https://assetmemo.bio/drug/epcoritamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04792502-3126@assetmemo.bio
DTSTAMP:20261121T005642Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Lenalidomide: Phase 2 readout est. (NCT04792502)
DESCRIPTION:Lenalidomide\, phase 2\, Follicular Lymphoma.\nStudy: Mosunetuz
 umab With Lenalidomide Augmentation as First-line Therapy for Follicular a
 nd Marginal Zone Lymphoma\nEstimated primary completion: 31 August 2027. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/lenalidomide#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT04792502
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06151080-3126@assetmemo.bio
DTSTAMP:20261121T005642Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Lenalidomide: Phase 2 readout est. (NCT06151080)
DESCRIPTION:Lenalidomide\, phase 2\, Follicular Lymphoma.\nStudy: Lenalidom
 ide Combined With G-CHOP in the Treatment of Newly Diagnosed DLBCL With FL
 \nEstimated primary completion: 31 August 2027. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/lenalidomide#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT06151080
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04542824-3126@assetmemo.bio
DTSTAMP:20261121T005642Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Lenalidomide: Phase 1/2 readout est. (NCT04542824)
DESCRIPTION:Lenalidomide\, phase 1/2\, Follicular Lymphoma.\nStudy: Trial o
 f the Safety and Efficacy of Epcoritamab in Japanese Subjects With Relapse
 d or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (R/R B-NHL)\nEstimated p
 rimary completion: September 2027. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/lenalidomide#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT04542824
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04542824-4915@assetmemo.bio
DTSTAMP:20261121T005642Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Rituxan (Rituximab): Phase 1/2 readout est. (NCT04542824)
DESCRIPTION:Rituxan (Rituximab)\, phase 1/2\, Diffuse Large B-Cell Lymphoma
 .\nStudy: Trial of the Safety and Efficacy of Epcoritamab in Japanese Subj
 ects With Relapsed or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (R/R B-
 NHL)\nEstimated primary completion: September 2027. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/rituximab#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT04542824
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04542824-10986@assetmemo.bio
DTSTAMP:20261121T005642Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Epcoritamab: Phase 1/2 readout est. (NCT04542824)
DESCRIPTION:Epcoritamab\, phase 1/2\, Diffuse Large B-Cell Lymphoma.\nStudy
 : Trial of the Safety and Efficacy of Epcoritamab in Japanese Subjects Wit
 h Relapsed or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (R/R B-NHL)\nEs
 timated primary completion: September 2027. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/epcoritamab#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT04542824
URL:https://assetmemo.bio/drug/epcoritamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04663347-3126@assetmemo.bio
DTSTAMP:20261121T005642Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Lenalidomide: Phase 1/2 readout est. (NCT04663347)
DESCRIPTION:Lenalidomide\, phase 1/2\, Follicular Lymphoma.\nStudy: Safety 
 and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non
 -Hodgkin Lymphoma (B-NHL)\nEstimated primary completion: 30 September 2027
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/lenalidomide#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT04663347
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05683171-3126@assetmemo.bio
DTSTAMP:20261121T005642Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Lenalidomide: Phase 1/2 readout est. (NCT05683171)
DESCRIPTION:Lenalidomide\, phase 1/2\, Follicular Lymphoma.\nStudy: A Phase
  1/2\, Open-label Study of Valemetostat in Combination With Rituximab and 
 Lenalidomide in Relapsed or Refractory Follicular Lymphoma\nEstimated prim
 ary completion: 30 September 2027. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/lenalidomide#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT05683171
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04663347-4915@assetmemo.bio
DTSTAMP:20261121T005642Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Rituxan (Rituximab): Phase 1/2 readout est. (NCT04663347)
DESCRIPTION:Rituxan (Rituximab)\, phase 1/2\, Diffuse Large B-Cell Lymphoma
 .\nStudy: Safety and Efficacy Trial of Epcoritamab Combinations in Subject
 s With B-cell Non-Hodgkin Lymphoma (B-NHL)\nEstimated primary completion: 
 30 September 2027. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ri
 tuximab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT04663347
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05683171-4915@assetmemo.bio
DTSTAMP:20261121T005642Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Rituxan (Rituximab): Phase 1/2 readout est. (NCT05683171)
DESCRIPTION:Rituxan (Rituximab)\, phase 1/2\, Follicular Lymphoma.\nStudy: 
 A Phase 1/2\, Open-label Study of Valemetostat in Combination With Rituxim
 ab and Lenalidomide in Relapsed or Refractory Follicular Lymphoma\nEstimat
 ed primary completion: 30 September 2027. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/rituximab#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT05683171
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04663347-10986@assetmemo.bio
DTSTAMP:20261121T005642Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Epcoritamab: Phase 1/2 readout est. (NCT04663347)
DESCRIPTION:Epcoritamab\, phase 1/2\, Diffuse Large B-Cell Lymphoma.\nStudy
 : Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B
 -cell Non-Hodgkin Lymphoma (B-NHL)\nEstimated primary completion: 30 Septe
 mber 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/epcoritama
 b#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT04
 663347
URL:https://assetmemo.bio/drug/epcoritamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06474481-2649@assetmemo.bio
DTSTAMP:20261121T005642Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Obinutuzumab: Phase 2 readout est. (NCT06474481)
DESCRIPTION:Obinutuzumab\, phase 2\, Follicular Lymphoma.\nStudy: Zanubruti
 nib and G-CHOP in Untreated Intermediate-high Risk Follicular Lymphoma\nEs
 timated primary completion: December 2027. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/obinutuzumab#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT06474481
URL:https://assetmemo.bio/drug/obinutuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06474481-10908@assetmemo.bio
DTSTAMP:20261121T005642Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Brukinsa (zanubrutinib): Phase 2 readout est. (NCT06474481)
DESCRIPTION:Brukinsa (zanubrutinib)\, phase 2\, Follicular Lymphoma.\nStudy
 : Zanubrutinib and G-CHOP in Untreated Intermediate-high Risk Follicular L
 ymphoma\nEstimated primary completion: December 2027. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/zanubrutinib#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT06474481
URL:https://assetmemo.bio/drug/zanubrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05389293-10908@assetmemo.bio
DTSTAMP:20261121T005642Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Brukinsa (zanubrutinib): Phase 2 readout est. (NCT05389293)
DESCRIPTION:Brukinsa (zanubrutinib)\, phase 2\, Follicular Lymphoma.\nStudy
 : A Study of Mosunetuzumab Alone or With Zanubrutinib in People With Folli
 cular Lymphoma\nEstimated primary completion: December 2027. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/zanubrutinib#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT05389293
URL:https://assetmemo.bio/drug/zanubrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06108232-2649@assetmemo.bio
DTSTAMP:20261121T005642Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Obinutuzumab: Phase 2 readout est. (NCT06108232)
DESCRIPTION:Obinutuzumab\, phase 2\, Follicular Lymphoma.\nStudy: Phase 2 T
 rial of Obinutuzumab and CC-99282 for Patients With Previously Untreated H
 igh Tumor Burden Follicular Lymphoma\nEstimated primary completion: 31 Dec
 ember 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/obinutuzu
 mab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 06108232
URL:https://assetmemo.bio/drug/obinutuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07418190-3126@assetmemo.bio
DTSTAMP:20261121T005642Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Lenalidomide: Phase 2 readout est. (NCT07418190)
DESCRIPTION:Lenalidomide\, phase 2\, Follicular Lymphoma.\nStudy: Efficacy 
 and Safety of Zanubrutinib\, Rituximab\, and Lenalidomide (ZR²) in Combin
 ation With Tislelizumab for Relapsed/Refractory Follicular Lymphoma\nEstim
 ated primary completion: 31 December 2027. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/lenalidomide#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT07418190
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07418190-4915@assetmemo.bio
DTSTAMP:20261121T005642Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Rituxan (Rituximab): Phase 2 readout est. (NCT07418190)
DESCRIPTION:Rituxan (Rituximab)\, phase 2\, Follicular Lymphoma.\nStudy: Ef
 ficacy and Safety of Zanubrutinib\, Rituximab\, and Lenalidomide (ZR²) in
  Combination With Tislelizumab for Relapsed/Refractory Follicular Lymphoma
 \nEstimated primary completion: 31 December 2027. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/rituximab#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT07418190
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07418190-10908@assetmemo.bio
DTSTAMP:20261121T005642Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Brukinsa (zanubrutinib): Phase 2 readout est. (NCT07418190)
DESCRIPTION:Brukinsa (zanubrutinib)\, phase 2\, Follicular Lymphoma.\nStudy
 : Efficacy and Safety of Zanubrutinib\, Rituximab\, and Lenalidomide (ZR²
 ) in Combination With Tislelizumab for Relapsed/Refractory Follicular Lymp
 homa\nEstimated primary completion: 31 December 2027. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/zanubrutinib#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT07418190
URL:https://assetmemo.bio/drug/zanubrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05788081-4915@assetmemo.bio
DTSTAMP:20261121T005642Z
DTSTART;VALUE=DATE:20280101
DTEND;VALUE=DATE:20280102
SUMMARY:Rituxan (Rituximab): Phase 2 readout est. (NCT05788081)
DESCRIPTION:Rituxan (Rituximab)\, phase 2\, Follicular Lymphoma.\nStudy: Tr
 eatment Of Newly-diagnosed Follicular Lymphoma With CELMoD Golcadomide\, R
 ituximab +/- Nivolumab.\nEstimated primary completion: 1 January 2028. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/rituximab#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT05788081
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05783609-4915@assetmemo.bio
DTSTAMP:20261121T005642Z
DTSTART;VALUE=DATE:20280229
DTEND;VALUE=DATE:20280301
SUMMARY:Rituxan (Rituximab): Phase 2 readout est. (NCT05783609)
DESCRIPTION:Rituxan (Rituximab)\, phase 2\, Follicular Lymphoma.\nStudy: Ep
 coritamab and Rituximab for First-line Follicular Lymphoma\nEstimated prim
 ary completion: February 2028. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/rituximab#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT05783609
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05783609-10986@assetmemo.bio
DTSTAMP:20261121T005642Z
DTSTART;VALUE=DATE:20280229
DTEND;VALUE=DATE:20280301
SUMMARY:Epcoritamab: Phase 2 readout est. (NCT05783609)
DESCRIPTION:Epcoritamab\, phase 2\, Follicular Lymphoma.\nStudy: Epcoritama
 b and Rituximab for First-line Follicular Lymphoma\nEstimated primary comp
 letion: February 2028. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/epcoritamab#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT05783609
URL:https://assetmemo.bio/drug/epcoritamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06091254-5820@assetmemo.bio
DTSTAMP:20261121T005642Z
DTSTART;VALUE=DATE:20280229
DTEND;VALUE=DATE:20280301
SUMMARY:Odronextamab: Phase 3 readout est. (NCT06091254)
DESCRIPTION:Odronextamab\, phase 3\, Follicular Lymphoma.\nStudy: A Trial t
 o Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works C
 ompared to Rituximab Combined With Different Types of Chemotherapy for Adu
 lt Participants With Previously Untreated Follicular Lymphoma\nEstimated p
 rimary completion: 29 February 2028. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/odronextamab#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT06091254
URL:https://assetmemo.bio/drug/odronextamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04404088-3126@assetmemo.bio
DTSTAMP:20261121T005642Z
DTSTART;VALUE=DATE:20280301
DTEND;VALUE=DATE:20280302
SUMMARY:Lenalidomide: Phase 2 readout est. (NCT04404088)
DESCRIPTION:Lenalidomide\, phase 2\, Follicular Lymphoma.\nStudy: Acalabrut
 inib\, Lenalidomide\, and Rituximab for the Treatment of CD20 Positive Sta
 ge III-IV\, Grade 1-3a Follicular Lymphoma\nEstimated primary completion: 
 1 March 2028. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/lenalid
 omide#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT04404088
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04404088-4915@assetmemo.bio
DTSTAMP:20261121T005642Z
DTSTART;VALUE=DATE:20280301
DTEND;VALUE=DATE:20280302
SUMMARY:Rituxan (Rituximab): Phase 2 readout est. (NCT04404088)
DESCRIPTION:Rituxan (Rituximab)\, phase 2\, Follicular Lymphoma.\nStudy: Ac
 alabrutinib\, Lenalidomide\, and Rituximab for the Treatment of CD20 Posit
 ive Stage III-IV\, Grade 1-3a Follicular Lymphoma\nEstimated primary compl
 etion: 1 March 2028. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 rituximab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT04404088
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05025800-3126@assetmemo.bio
DTSTAMP:20261121T005642Z
DTSTART;VALUE=DATE:20280321
DTEND;VALUE=DATE:20280322
SUMMARY:Lenalidomide: Phase 1/2 readout est. (NCT05025800)
DESCRIPTION:Lenalidomide\, phase 1/2\, Follicular Lymphoma.\nStudy: ALX148\
 , Rituximab and Lenalidomide for the Treatment of Indolent and Aggressive 
 B-cell Non-Hodgkin Lymphoma\nEstimated primary completion: 21 March 2028. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/lenalidomide#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT05025800
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05025800-4915@assetmemo.bio
DTSTAMP:20261121T005642Z
DTSTART;VALUE=DATE:20280321
DTEND;VALUE=DATE:20280322
SUMMARY:Rituxan (Rituximab): Phase 1/2 readout est. (NCT05025800)
DESCRIPTION:Rituxan (Rituximab)\, phase 1/2\, Diffuse Large B-Cell Lymphoma
 .\nStudy: ALX148\, Rituximab and Lenalidomide for the Treatment of Indolen
 t and Aggressive B-cell Non-Hodgkin Lymphoma\nEstimated primary completion
 : 21 March 2028. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ritu
 ximab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT05025800
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07550855-4915@assetmemo.bio
DTSTAMP:20261121T005642Z
DTSTART;VALUE=DATE:20280330
DTEND;VALUE=DATE:20280331
SUMMARY:Rituxan (Rituximab): Phase 2 readout est. (NCT07550855)
DESCRIPTION:Rituxan (Rituximab)\, phase 2\, Follicular Lymphoma.\nStudy: So
 nrotoclax\, Zanubrutinib and Rituximab in Previously Untreated Patients Wi
 th Follicular Lymphoma\nEstimated primary completion: 30 March 2028. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/rituximab#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT07550855
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07550855-10908@assetmemo.bio
DTSTAMP:20261121T005642Z
DTSTART;VALUE=DATE:20280330
DTEND;VALUE=DATE:20280331
SUMMARY:Brukinsa (zanubrutinib): Phase 2 readout est. (NCT07550855)
DESCRIPTION:Brukinsa (zanubrutinib)\, phase 2\, Follicular Lymphoma.\nStudy
 : Sonrotoclax\, Zanubrutinib and Rituximab in Previously Untreated Patient
 s With Follicular Lymphoma\nEstimated primary completion: 30 March 2028. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/zanubrutinib#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT07550855
URL:https://assetmemo.bio/drug/zanubrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06784726-5820@assetmemo.bio
DTSTAMP:20261121T005642Z
DTSTART;VALUE=DATE:20280410
DTEND;VALUE=DATE:20280411
SUMMARY:Odronextamab: Phase 2 readout est. (NCT06784726)
DESCRIPTION:Odronextamab\, phase 2\, Diffuse Large B-Cell Lymphoma.\nStudy:
  Odronextamab for Relapsed and Refractory Large B-cell Lymphomas Before CA
 R-T\nEstimated primary completion: 10 April 2028. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/odronextamab#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT06784726
URL:https://assetmemo.bio/drug/odronextamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06526793-5561@assetmemo.bio
DTSTAMP:20261121T005642Z
DTSTART;VALUE=DATE:20280421
DTEND;VALUE=DATE:20280422
SUMMARY:Surovatamig: Phase 2 readout est. (NCT06526793)
DESCRIPTION:Surovatamig\, phase 2\, Follicular Lymphoma.\nStudy: Surovatami
 g (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) 
 B-cell NHL\nEstimated primary completion: 21 April 2028. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/surovatamig#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT06526793
URL:https://assetmemo.bio/drug/surovatamig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06911502-4915@assetmemo.bio
DTSTAMP:20261121T005642Z
DTSTART;VALUE=DATE:20280424
DTEND;VALUE=DATE:20280425
SUMMARY:Rituxan (Rituximab): Phase 3 readout est. (NCT06911502)
DESCRIPTION:Rituxan (Rituximab)\, phase 3\, Follicular Lymphoma.\nStudy: A 
 Study to Compare the Efficacy and Safety of Golcadomide in Combination Wit
 h Rituximab (Golca + R) vs Investigator's Choice in Participants With Rela
 psed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Lin
 e of Systemic Therapy (GOLSEEK-4)\nEstimated primary completion: 24 April 
 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/rituximab#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT06911502
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07299149-2649@assetmemo.bio
DTSTAMP:20261121T005642Z
DTSTART;VALUE=DATE:20280428
DTEND;VALUE=DATE:20280429
SUMMARY:Obinutuzumab: Phase 2 readout est. (NCT07299149)
DESCRIPTION:Obinutuzumab\, phase 2\, Follicular Lymphoma.\nStudy: Zanubruti
 nib\, Obinutuzumab Combined With Lenalidomide (ZGR) for the Treatment of U
 ntreated Follicular Lymphoma\nEstimated primary completion: 28 April 2028.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/obinutuzumab#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT07299149
URL:https://assetmemo.bio/drug/obinutuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07299149-3126@assetmemo.bio
DTSTAMP:20261121T005642Z
DTSTART;VALUE=DATE:20280428
DTEND;VALUE=DATE:20280429
SUMMARY:Lenalidomide: Phase 2 readout est. (NCT07299149)
DESCRIPTION:Lenalidomide\, phase 2\, Follicular Lymphoma.\nStudy: Zanubruti
 nib\, Obinutuzumab Combined With Lenalidomide (ZGR) for the Treatment of U
 ntreated Follicular Lymphoma\nEstimated primary completion: 28 April 2028.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/lenalidomide#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT07299149
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07299149-10908@assetmemo.bio
DTSTAMP:20261121T005642Z
DTSTART;VALUE=DATE:20280428
DTEND;VALUE=DATE:20280429
SUMMARY:Brukinsa (zanubrutinib): Phase 2 readout est. (NCT07299149)
DESCRIPTION:Brukinsa (zanubrutinib)\, phase 2\, Follicular Lymphoma.\nStudy
 : Zanubrutinib\, Obinutuzumab Combined With Lenalidomide (ZGR) for the Tre
 atment of Untreated Follicular Lymphoma\nEstimated primary completion: 28 
 April 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/zanubruti
 nib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 07299149
URL:https://assetmemo.bio/drug/zanubrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07562022-3126@assetmemo.bio
DTSTAMP:20261121T005642Z
DTSTART;VALUE=DATE:20280531
DTEND;VALUE=DATE:20280601
SUMMARY:Lenalidomide: Phase 3 readout est. (NCT07562022)
DESCRIPTION:Lenalidomide\, phase 3\, Follicular Lymphoma.\nStudy: A Study t
 o Evaluate the Safety and Efficacy of SCTB35 in Combination With Lenalidom
 ide in Patients With Relapsed or Refractory Follicular Lymphoma\nEstimated
  primary completion: May 2028. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/lenalidomide#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT07562022
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06918015-2649@assetmemo.bio
DTSTAMP:20261121T005642Z
DTSTART;VALUE=DATE:20280501
DTEND;VALUE=DATE:20280502
SUMMARY:Obinutuzumab: Phase 2 readout est. (NCT06918015)
DESCRIPTION:Obinutuzumab\, phase 2\, Follicular Lymphoma.\nStudy: Zanubruti
 nib Plus GCVP (Obinutuzumab\, Cyclophosphamide\, Vindesine\, Prednisolone)
  in Previously Untreated Follicular Lymphoma\nEstimated primary completion
 : 1 May 2028. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/obinutu
 zumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT06918015
URL:https://assetmemo.bio/drug/obinutuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06918015-10908@assetmemo.bio
DTSTAMP:20261121T005642Z
DTSTART;VALUE=DATE:20280501
DTEND;VALUE=DATE:20280502
SUMMARY:Brukinsa (zanubrutinib): Phase 2 readout est. (NCT06918015)
DESCRIPTION:Brukinsa (zanubrutinib)\, phase 2\, Follicular Lymphoma.\nStudy
 : Zanubrutinib Plus GCVP (Obinutuzumab\, Cyclophosphamide\, Vindesine\, Pr
 ednisolone) in Previously Untreated Follicular Lymphoma\nEstimated primary
  completion: 1 May 2028. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/zanubrutinib#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT06918015
URL:https://assetmemo.bio/drug/zanubrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07814001-3126@assetmemo.bio
DTSTAMP:20261121T005642Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Lenalidomide: Phase 2 readout est. (NCT07814001)
DESCRIPTION:Lenalidomide\, phase 2\, Follicular Lymphoma.\nStudy: Epcoritam
 ab Plus Lenalidomide in Relapsed/Refractory Large B-cell Lymphoma After Se
 cond-Line CAR T-cell Therapy\nEstimated primary completion: July 2028. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/lenalidomide#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT07814001
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07814001-10986@assetmemo.bio
DTSTAMP:20261121T005642Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Epcoritamab: Phase 2 readout est. (NCT07814001)
DESCRIPTION:Epcoritamab\, phase 2\, Diffuse Large B-Cell Lymphoma.\nStudy: 
 Epcoritamab Plus Lenalidomide in Relapsed/Refractory Large B-cell Lymphoma
  After Second-Line CAR T-cell Therapy\nEstimated primary completion: July 
 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/epcoritamab#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0781400
 1
URL:https://assetmemo.bio/drug/epcoritamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05100862-2649@assetmemo.bio
DTSTAMP:20261121T005642Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Obinutuzumab: Phase 3 readout est. (NCT05100862)
DESCRIPTION:Obinutuzumab\, phase 3\, Follicular Lymphoma.\nStudy: A Study o
 f Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Partic
 ipants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma\nEsti
 mated primary completion: July 2028. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/obinutuzumab#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT05100862
URL:https://assetmemo.bio/drug/obinutuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05058404-4915@assetmemo.bio
DTSTAMP:20261121T005642Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Rituxan (Rituximab): Phase 3 readout est. (NCT05058404)
DESCRIPTION:Rituxan (Rituximab)\, phase 3\, Follicular Lymphoma.\nStudy: Sh
 ortened vs Standard Chemotherapy Combined With Immunotherapy for the Initi
 al Treatment of Patients With High Tumor Burden Follicular Lymphoma\nEstim
 ated primary completion: July 2028. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/rituximab#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT05058404
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05100862-10908@assetmemo.bio
DTSTAMP:20261121T005642Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Brukinsa (zanubrutinib): Phase 3 readout est. (NCT05100862)
DESCRIPTION:Brukinsa (zanubrutinib)\, phase 3\, Follicular Lymphoma.\nStudy
 : A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituxima
 b in Participants With Relapsed/Refractory Follicular or Marginal Zone Lym
 phoma\nEstimated primary completion: July 2028. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/zanubrutinib#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT05100862
URL:https://assetmemo.bio/drug/zanubrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06905509-4915@assetmemo.bio
DTSTAMP:20261121T005642Z
DTSTART;VALUE=DATE:20280701
DTEND;VALUE=DATE:20280702
SUMMARY:Rituxan (Rituximab): Phase 2 readout est. (NCT06905509)
DESCRIPTION:Rituxan (Rituximab)\, phase 2\, Diffuse Large B-Cell Lymphoma.\
 nStudy: Epcoritamab Plus Standard of Care Platinum-Based Chemotherapy and 
 Autologous Hematopoietic Cell Transplant for the Treatment of Relapsed or 
 Refractory Large B-cell Lymphoma\nEstimated primary completion: 1 July 202
 8. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/rituximab#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT06905509
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06905509-10986@assetmemo.bio
DTSTAMP:20261121T005642Z
DTSTART;VALUE=DATE:20280701
DTEND;VALUE=DATE:20280702
SUMMARY:Epcoritamab: Phase 2 readout est. (NCT06905509)
DESCRIPTION:Epcoritamab\, phase 2\, Diffuse Large B-Cell Lymphoma.\nStudy: 
 Epcoritamab Plus Standard of Care Platinum-Based Chemotherapy and Autologo
 us Hematopoietic Cell Transplant for the Treatment of Relapsed or Refracto
 ry Large B-cell Lymphoma\nEstimated primary completion: 1 July 2028. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/epcoritamab#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT06905509
URL:https://assetmemo.bio/drug/epcoritamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06492837-10908@assetmemo.bio
DTSTAMP:20261121T005642Z
DTSTART;VALUE=DATE:20280915
DTEND;VALUE=DATE:20280916
SUMMARY:Brukinsa (zanubrutinib): Phase 2 readout est. (NCT06492837)
DESCRIPTION:Brukinsa (zanubrutinib)\, phase 2\, Follicular Lymphoma.\nStudy
 : Study With Mosunetuzumab and Zanubrutinib in R/R Follicular Lymphoma Pat
 ients\nEstimated primary completion: 15 September 2028. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/zanubrutinib#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT06492837
URL:https://assetmemo.bio/drug/zanubrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06854159-5820@assetmemo.bio
DTSTAMP:20261121T005642Z
DTSTART;VALUE=DATE:20281031
DTEND;VALUE=DATE:20281101
SUMMARY:Odronextamab: Phase 2 readout est. (NCT06854159)
DESCRIPTION:Odronextamab\, phase 2\, Diffuse Large B-Cell Lymphoma.\nStudy:
  Odronextamab for the Treatment of Relapsed and Refractory Diffuse Large B
 -cell Lymphoma Before and After Chimeric Antigen Receptor T-cell Therapy\n
 Estimated primary completion: October 2028. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/odronextamab#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT06854159
URL:https://assetmemo.bio/drug/odronextamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06284122-3126@assetmemo.bio
DTSTAMP:20261121T005642Z
DTSTART;VALUE=DATE:20281130
DTEND;VALUE=DATE:20281201
SUMMARY:Lenalidomide: Phase 3 readout est. (NCT06284122)
DESCRIPTION:Lenalidomide\, phase 3\, Follicular Lymphoma.\nStudy: Study of 
 Mosunetuzumab Plus Lenalidomide Compared to Anti-CD20 Anti-body + Chemothe
 rapy in Follicular Lymphoma FLIPI2-5\nEstimated primary completion: Novemb
 er 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/lenalidomide
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT062
 84122
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07783594-10986@assetmemo.bio
DTSTAMP:20261121T005642Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Epcoritamab: Phase 2 readout est. (NCT07783594)
DESCRIPTION:Epcoritamab\, phase 2\, Follicular Lymphoma.\nStudy: Randomized
  Phase 2 Study Of Epcoritamab Vs Watch And Wait InPatients With Previously
  Untreated Low Tumor Burden FollicularLymphoma\nEstimated primary completi
 on: 31 December 2028. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /epcoritamab#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT07783594
URL:https://assetmemo.bio/drug/epcoritamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06350318-4915@assetmemo.bio
DTSTAMP:20261121T005642Z
DTSTART;VALUE=DATE:20290331
DTEND;VALUE=DATE:20290401
SUMMARY:Rituxan (Rituximab): Phase 2 readout est. (NCT06350318)
DESCRIPTION:Rituxan (Rituximab)\, phase 2\, Follicular Lymphoma.\nStudy: Ri
 tuximab and Zanubrutinib in Patients With Indolent B-cell Lymphomas\nEstim
 ated primary completion: March 2029. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/rituximab#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT06350318
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06350318-10908@assetmemo.bio
DTSTAMP:20261121T005642Z
DTSTART;VALUE=DATE:20290331
DTEND;VALUE=DATE:20290401
SUMMARY:Brukinsa (zanubrutinib): Phase 2 readout est. (NCT06350318)
DESCRIPTION:Brukinsa (zanubrutinib)\, phase 2\, Follicular Lymphoma.\nStudy
 : Rituximab and Zanubrutinib in Patients With Indolent B-cell Lymphomas\nE
 stimated primary completion: March 2029. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/zanubrutinib#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT06350318
URL:https://assetmemo.bio/drug/zanubrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04669171-3126@assetmemo.bio
DTSTAMP:20261121T005642Z
DTSTART;VALUE=DATE:20290530
DTEND;VALUE=DATE:20290531
SUMMARY:Lenalidomide: Phase 1/2 readout est. (NCT04669171)
DESCRIPTION:Lenalidomide\, phase 1/2\, Follicular Lymphoma.\nStudy: A Novel
  Vaccine (EO2463) as Monotherapy and in Combination\, for Treatment of Pat
 ients With Indolent Non-Hodgkin Lymphoma\nEstimated primary completion: 30
  May 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/lenalidomi
 de#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 4669171
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04669171-4915@assetmemo.bio
DTSTAMP:20261121T005642Z
DTSTART;VALUE=DATE:20290530
DTEND;VALUE=DATE:20290531
SUMMARY:Rituxan (Rituximab): Phase 1/2 readout est. (NCT04669171)
DESCRIPTION:Rituxan (Rituximab)\, phase 1/2\, Follicular Lymphoma.\nStudy: 
 A Novel Vaccine (EO2463) as Monotherapy and in Combination\, for Treatment
  of Patients With Indolent Non-Hodgkin Lymphoma\nEstimated primary complet
 ion: 30 May 2029. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/rit
 uximab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT04669171
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05848765-3126@assetmemo.bio
DTSTAMP:20261121T005642Z
DTSTART;VALUE=DATE:20290531
DTEND;VALUE=DATE:20290601
SUMMARY:Lenalidomide: Phase 2 readout est. (NCT05848765)
DESCRIPTION:Lenalidomide\, phase 2\, Follicular Lymphoma.\nStudy: Relapsed 
 Follicular Lymphoma Randomised Trial Against Standard ChemoTherapy\nEstima
 ted primary completion: 31 May 2029. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/lenalidomide#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT05848765
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05848765-10986@assetmemo.bio
DTSTAMP:20261121T005642Z
DTSTART;VALUE=DATE:20290531
DTEND;VALUE=DATE:20290601
SUMMARY:Epcoritamab: Phase 2 readout est. (NCT05848765)
DESCRIPTION:Epcoritamab\, phase 2\, Follicular Lymphoma.\nStudy: Relapsed F
 ollicular Lymphoma Randomised Trial Against Standard ChemoTherapy\nEstimat
 ed primary completion: 31 May 2029. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/epcoritamab#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT05848765
URL:https://assetmemo.bio/drug/epcoritamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06792825-3126@assetmemo.bio
DTSTAMP:20261121T005642Z
DTSTART;VALUE=DATE:20290708
DTEND;VALUE=DATE:20290709
SUMMARY:Lenalidomide: Phase 2 readout est. (NCT06792825)
DESCRIPTION:Lenalidomide\, phase 2\, Follicular Lymphoma.\nStudy: HM2023-43
 :Ph 2 Trial of Tafasitamab With Lenalidomide+Rituximab in Treatment-naive 
 FL and MZL\nEstimated primary completion: 8 July 2029. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/lenalidomide#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT06792825
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06792825-4915@assetmemo.bio
DTSTAMP:20261121T005642Z
DTSTART;VALUE=DATE:20290708
DTEND;VALUE=DATE:20290709
SUMMARY:Rituxan (Rituximab): Phase 2 readout est. (NCT06792825)
DESCRIPTION:Rituxan (Rituximab)\, phase 2\, Follicular Lymphoma.\nStudy: HM
 2023-43:Ph 2 Trial of Tafasitamab With Lenalidomide+Rituximab in Treatment
 -naive FL and MZL\nEstimated primary completion: 8 July 2029. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/rituximab#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT06792825
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06792825-5647@assetmemo.bio
DTSTAMP:20261121T005642Z
DTSTART;VALUE=DATE:20290708
DTEND;VALUE=DATE:20290709
SUMMARY:Tafasitamab: Phase 2 readout est. (NCT06792825)
DESCRIPTION:Tafasitamab\, phase 2\, Follicular Lymphoma.\nStudy: HM2023-43:
 Ph 2 Trial of Tafasitamab With Lenalidomide+Rituximab in Treatment-naive F
 L and MZL\nEstimated primary completion: 8 July 2029. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/tafasitamab#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT06792825
URL:https://assetmemo.bio/drug/tafasitamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06097364-5820@assetmemo.bio
DTSTAMP:20261121T005642Z
DTSTART;VALUE=DATE:20290729
DTEND;VALUE=DATE:20290730
SUMMARY:Odronextamab: Phase 3 readout est. (NCT06097364)
DESCRIPTION:Odronextamab\, phase 3\, Follicular Lymphoma.\nStudy: A Trial t
 o Learn if Odronextamab Combined With Chemotherapy is Safe and Well-Tolera
 ted and How Well it Works Compared to Rituximab Combined With Chemotherapy
  for Adult Participants With Follicular Lymphoma\nEstimated primary comple
 tion: 29 July 2029. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/o
 dronextamab#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT06097364
URL:https://assetmemo.bio/drug/odronextamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05409066-3126@assetmemo.bio
DTSTAMP:20261121T005642Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Lenalidomide: Phase 3 readout est. (NCT05409066)
DESCRIPTION:Lenalidomide\, phase 3\, Follicular Lymphoma.\nStudy: Study of 
 Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Ora
 l Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activit
 y in Adult Participants With Follicular Lymphoma\nEstimated primary comple
 tion: December 2029. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 lenalidomide#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT05409066
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05409066-4915@assetmemo.bio
DTSTAMP:20261121T005642Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Rituxan (Rituximab): Phase 3 readout est. (NCT05409066)
DESCRIPTION:Rituxan (Rituximab)\, phase 3\, Follicular Lymphoma.\nStudy: St
 udy of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab 
 and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease 
 Activity in Adult Participants With Follicular Lymphoma\nEstimated primary
  completion: December 2029. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/rituximab#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT05409066
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05409066-10986@assetmemo.bio
DTSTAMP:20261121T005642Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Epcoritamab: Phase 3 readout est. (NCT05409066)
DESCRIPTION:Epcoritamab\, phase 3\, Follicular Lymphoma.\nStudy: Study of S
 ubcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral
  Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity
  in Adult Participants With Follicular Lymphoma\nEstimated primary complet
 ion: December 2029. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/e
 pcoritamab#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT05409066
URL:https://assetmemo.bio/drug/epcoritamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05890352-3126@assetmemo.bio
DTSTAMP:20261121T005642Z
DTSTART;VALUE=DATE:20291201
DTEND;VALUE=DATE:20291202
SUMMARY:Lenalidomide: Phase 2 readout est. (NCT05890352)
DESCRIPTION:Lenalidomide\, phase 2\, Follicular Lymphoma.\nStudy: Study Add
 ing Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Di
 d Not Respond to Treatment\nEstimated primary completion: 1 December 2029.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/lenalidomide#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT05890352
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05890352-5647@assetmemo.bio
DTSTAMP:20261121T005642Z
DTSTART;VALUE=DATE:20291201
DTEND;VALUE=DATE:20291202
SUMMARY:Tafasitamab: Phase 2 readout est. (NCT05890352)
DESCRIPTION:Tafasitamab\, phase 2\, Diffuse Large B-Cell Lymphoma.\nStudy: 
 Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Retur
 ned or Did Not Respond to Treatment\nEstimated primary completion: 1 Decem
 ber 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/tafasitamab
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT058
 90352
URL:https://assetmemo.bio/drug/tafasitamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05890352-10908@assetmemo.bio
DTSTAMP:20261121T005642Z
DTSTART;VALUE=DATE:20291201
DTEND;VALUE=DATE:20291202
SUMMARY:Brukinsa (zanubrutinib): Phase 2 readout est. (NCT05890352)
DESCRIPTION:Brukinsa (zanubrutinib)\, phase 2\, Follicular Lymphoma.\nStudy
 : Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Ret
 urned or Did Not Respond to Treatment\nEstimated primary completion: 1 Dec
 ember 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/zanubruti
 nib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 05890352
URL:https://assetmemo.bio/drug/zanubrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07585747-3126@assetmemo.bio
DTSTAMP:20261121T005642Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Lenalidomide: Phase 2 readout est. (NCT07585747)
DESCRIPTION:Lenalidomide\, phase 2\, Follicular Lymphoma.\nStudy: A Explora
 tory Study on Untreated Follicular Lymphoma With Orelabrutinib\, Tafasitam
 ab\, and Lenalidomide\nEstimated primary completion: 31 December 2029. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/lenalidomide#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT07585747
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07585747-5647@assetmemo.bio
DTSTAMP:20261121T005642Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Tafasitamab: Phase 2 readout est. (NCT07585747)
DESCRIPTION:Tafasitamab\, phase 2\, Follicular Lymphoma.\nStudy: A Explorat
 ory Study on Untreated Follicular Lymphoma With Orelabrutinib\, Tafasitama
 b\, and Lenalidomide\nEstimated primary completion: 31 December 2029. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/tafasitamab#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT07585747
URL:https://assetmemo.bio/drug/tafasitamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05643742-5691@assetmemo.bio
DTSTAMP:20261121T005642Z
DTSTART;VALUE=DATE:20300131
DTEND;VALUE=DATE:20300201
SUMMARY:Zugocabtagene geleucel: Phase 1/2 readout est. (NCT05643742)
DESCRIPTION:Zugocabtagene geleucel\, phase 1/2\, Follicular Lymphoma.\nStud
 y: A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed
  or Refractory B-Cell Malignancies\nEstimated primary completion: January 
 2030. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/zugocabtagene-g
 eleucel#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT05643742
URL:https://assetmemo.bio/drug/zugocabtagene-geleucel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06563596-4915@assetmemo.bio
DTSTAMP:20261121T005642Z
DTSTART;VALUE=DATE:20300301
DTEND;VALUE=DATE:20300302
SUMMARY:Rituxan (Rituximab): Phase 2 readout est. (NCT06563596)
DESCRIPTION:Rituxan (Rituximab)\, phase 2\, Follicular Lymphoma.\nStudy: Ep
 co\, Zanu\, Ritux for R/R FL or MZL\nEstimated primary completion: 1 March
  2030. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/rituximab#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06563596
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06563596-10908@assetmemo.bio
DTSTAMP:20261121T005642Z
DTSTART;VALUE=DATE:20300301
DTEND;VALUE=DATE:20300302
SUMMARY:Brukinsa (zanubrutinib): Phase 2 readout est. (NCT06563596)
DESCRIPTION:Brukinsa (zanubrutinib)\, phase 2\, Follicular Lymphoma.\nStudy
 : Epco\, Zanu\, Ritux for R/R FL or MZL\nEstimated primary completion: 1 M
 arch 2030. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/zanubrutin
 ib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 6563596
URL:https://assetmemo.bio/drug/zanubrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06563596-10986@assetmemo.bio
DTSTAMP:20261121T005642Z
DTSTART;VALUE=DATE:20300301
DTEND;VALUE=DATE:20300302
SUMMARY:Epcoritamab: Phase 2 readout est. (NCT06563596)
DESCRIPTION:Epcoritamab\, phase 2\, Follicular Lymphoma.\nStudy: Epco\, Zan
 u\, Ritux for R/R FL or MZL\nEstimated primary completion: 1 March 2030. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/epcoritamab#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT06563596
URL:https://assetmemo.bio/drug/epcoritamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07505849-10908@assetmemo.bio
DTSTAMP:20261121T005642Z
DTSTART;VALUE=DATE:20300323
DTEND;VALUE=DATE:20300324
SUMMARY:Brukinsa (zanubrutinib): Phase 2 readout est. (NCT07505849)
DESCRIPTION:Brukinsa (zanubrutinib)\, phase 2\, Follicular Lymphoma.\nStudy
 : ZR2 Versus R2 Regimen in the Treatment of Newly Diagnosed Follicular Lym
 phoma\nEstimated primary completion: 23 March 2030. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/zanubrutinib#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT07505849
URL:https://assetmemo.bio/drug/zanubrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07197307-10986@assetmemo.bio
DTSTAMP:20261121T005642Z
DTSTART;VALUE=DATE:20300430
DTEND;VALUE=DATE:20300501
SUMMARY:Epcoritamab: Phase 2 readout est. (NCT07197307)
DESCRIPTION:Epcoritamab\, phase 2\, Diffuse Large B-Cell Lymphoma.\nStudy: 
 Combining Loncastuximab Tesirine and Epcoritamab in Relapsed/Refractory Di
 ffuse Large B-cell Lymphoma (DLBCL)\nEstimated primary completion: 30 Apri
 l 2030. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/epcoritamab#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07197
 307
URL:https://assetmemo.bio/drug/epcoritamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07719855-2649@assetmemo.bio
DTSTAMP:20261121T005642Z
DTSTART;VALUE=DATE:20300731
DTEND;VALUE=DATE:20300801
SUMMARY:Obinutuzumab: Phase 3 readout est. (NCT07719855)
DESCRIPTION:Obinutuzumab\, phase 3\, Follicular Lymphoma.\nStudy: A Multice
 nter\, Prospective\, Open-Label\, Randomized Controlled Clinical Study of 
 Orelabrutinib Combined With Obinutuzumab and Lenalidomide Versus Obinutuzu
 mab Plus Chemotherapy for Treatment-Naive Follicular Lymphoma\nEstimated p
 rimary completion: July 2030. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/obinutuzumab#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT07719855
URL:https://assetmemo.bio/drug/obinutuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07719855-3126@assetmemo.bio
DTSTAMP:20261121T005642Z
DTSTART;VALUE=DATE:20300731
DTEND;VALUE=DATE:20300801
SUMMARY:Lenalidomide: Phase 3 readout est. (NCT07719855)
DESCRIPTION:Lenalidomide\, phase 3\, Follicular Lymphoma.\nStudy: A Multice
 nter\, Prospective\, Open-Label\, Randomized Controlled Clinical Study of 
 Orelabrutinib Combined With Obinutuzumab and Lenalidomide Versus Obinutuzu
 mab Plus Chemotherapy for Treatment-Naive Follicular Lymphoma\nEstimated p
 rimary completion: July 2030. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/lenalidomide#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT07719855
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04246086-3126@assetmemo.bio
DTSTAMP:20261121T005642Z
DTSTART;VALUE=DATE:20300906
DTEND;VALUE=DATE:20300907
SUMMARY:Lenalidomide: Phase 1/2 readout est. (NCT04246086)
DESCRIPTION:Lenalidomide\, phase 1/2\, Follicular Lymphoma.\nStudy: A Study
  Evaluating the Safety\, Pharmacokinetics\, and Efficacy of Mosunetuzumab 
 + Lenalidomide (+Len)\, and the Safety\, Tolerability\, and Pharmacokineti
 cs of SC Versus IV Mosunetuzumab + Len in Participants With Follicular Lym
 phoma\nEstimated primary completion: 6 September 2030. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/lenalidomide#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT04246086
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07731789-4915@assetmemo.bio
DTSTAMP:20261121T005642Z
DTSTART;VALUE=DATE:20301031
DTEND;VALUE=DATE:20301101
SUMMARY:Rituxan (Rituximab): Phase 2 readout est. (NCT07731789)
DESCRIPTION:Rituxan (Rituximab)\, phase 2\, Follicular Lymphoma.\nStudy: Ta
 fasitamab and Rituximab for the Treatment of Newly Diagnosed Follicular Ly
 mphoma\nEstimated primary completion: 31 October 2030. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/rituximab#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT07731789
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07731789-5647@assetmemo.bio
DTSTAMP:20261121T005642Z
DTSTART;VALUE=DATE:20301031
DTEND;VALUE=DATE:20301101
SUMMARY:Tafasitamab: Phase 2 readout est. (NCT07731789)
DESCRIPTION:Tafasitamab\, phase 2\, Follicular Lymphoma.\nStudy: Tafasitama
 b and Rituximab for the Treatment of Newly Diagnosed Follicular Lymphoma\n
 Estimated primary completion: 31 October 2030. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/tafasitamab#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT07731789
URL:https://assetmemo.bio/drug/tafasitamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06961500-2649@assetmemo.bio
DTSTAMP:20261121T005642Z
DTSTART;VALUE=DATE:20301101
DTEND;VALUE=DATE:20301102
SUMMARY:Obinutuzumab: Phase 2 readout est. (NCT06961500)
DESCRIPTION:Obinutuzumab\, phase 2\, Follicular Lymphoma.\nStudy: Obinutuzu
 mab With CHOP Versus Obinutuzumab With Bendamustine in the Treatment of Ne
 wly Diagnosed Follicular Lymphoma Grade 3A\nEstimated primary completion: 
 1 November 2030. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/obin
 utuzumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT06961500
URL:https://assetmemo.bio/drug/obinutuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05929222-2649@assetmemo.bio
DTSTAMP:20261121T005642Z
DTSTART;VALUE=DATE:20310430
DTEND;VALUE=DATE:20310501
SUMMARY:Obinutuzumab: Phase 3 readout est. (NCT05929222)
DESCRIPTION:Obinutuzumab\, phase 3\, Follicular Lymphoma.\nStudy: Compariso
 n Between Local Radiotherapy Alone or Combined With Obinutuzumab in Early 
 Stage Follicular Lymphoma: the GAZEBO Trial From the Fondazione Italiana L
 infomi\nEstimated primary completion: April 2031. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/obinutuzumab#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT05929222
URL:https://assetmemo.bio/drug/obinutuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06149286-3126@assetmemo.bio
DTSTAMP:20261121T005642Z
DTSTART;VALUE=DATE:20310430
DTEND;VALUE=DATE:20310501
SUMMARY:Lenalidomide: Phase 3 readout est. (NCT06149286)
DESCRIPTION:Lenalidomide\, phase 3\, Follicular Lymphoma.\nStudy: A Trial t
 o Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Be
 tter Than Rituximab Combined With Lenalidomide in Adult Participants With 
 Follicular Lymphoma and Marginal Zone Lymphoma\nEstimated primary completi
 on: 30 April 2031. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/le
 nalidomide#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT06149286
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06149286-5820@assetmemo.bio
DTSTAMP:20261121T005642Z
DTSTART;VALUE=DATE:20310430
DTEND;VALUE=DATE:20310501
SUMMARY:Odronextamab: Phase 3 readout est. (NCT06149286)
DESCRIPTION:Odronextamab\, phase 3\, Follicular Lymphoma.\nStudy: A Trial t
 o Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Be
 tter Than Rituximab Combined With Lenalidomide in Adult Participants With 
 Follicular Lymphoma and Marginal Zone Lymphoma\nEstimated primary completi
 on: 30 April 2031. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/od
 ronextamab#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT06149286
URL:https://assetmemo.bio/drug/odronextamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06549595-5561@assetmemo.bio
DTSTAMP:20261121T005642Z
DTSTART;VALUE=DATE:20311126
DTEND;VALUE=DATE:20311127
SUMMARY:Surovatamig: Phase 3 readout est. (NCT06549595)
DESCRIPTION:Surovatamig\, phase 3\, Follicular Lymphoma.\nStudy: A Study of
  Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular L
 ymphoma Patients\nEstimated primary completion: 26 November 2031. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/surovatamig#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT06549595
URL:https://assetmemo.bio/drug/surovatamig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06337318-4915@assetmemo.bio
DTSTAMP:20261121T005642Z
DTSTART;VALUE=DATE:20320331
DTEND;VALUE=DATE:20320401
SUMMARY:Rituxan (Rituximab): Phase 3 readout est. (NCT06337318)
DESCRIPTION:Rituxan (Rituximab)\, phase 3\, Follicular Lymphoma.\nStudy: Co
 mparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tu
 mor Burden Follicular Lymphoma\nEstimated primary completion: 31 March 203
 2. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/rituximab#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT06337318
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07634471-4915@assetmemo.bio
DTSTAMP:20261121T005642Z
DTSTART;VALUE=DATE:20320723
DTEND;VALUE=DATE:20320724
SUMMARY:Rituxan (Rituximab): Phase 2/3 readout est. (NCT07634471)
DESCRIPTION:Rituxan (Rituximab)\, phase 2/3\, Follicular Lymphoma.\nStudy: 
 A Clinical Trial of MK-1045 and Rituximab in People With Follicular Lympho
 ma (MK-1045-007)\nEstimated primary completion: 23 July 2032. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/rituximab#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT07634471
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07736950-5561@assetmemo.bio
DTSTAMP:20261121T005642Z
DTSTART;VALUE=DATE:20350113
DTEND;VALUE=DATE:20350114
SUMMARY:Surovatamig: Phase 3 readout est. (NCT07736950)
DESCRIPTION:Surovatamig\, phase 3\, Follicular Lymphoma.\nStudy: A Study Co
 mparing a New Drug (Surovatamig) With Standard Radiotherapy With or Withou
 t Rituximab in Adults With Limited Stage Nodal Follicular Lymphoma\nEstima
 ted primary completion: 13 January 2035. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/surovatamig#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT07736950
URL:https://assetmemo.bio/drug/surovatamig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06191744-2649@assetmemo.bio
DTSTAMP:20261121T005642Z
DTSTART;VALUE=DATE:20371130
DTEND;VALUE=DATE:20371201
SUMMARY:Obinutuzumab: Phase 3 readout est. (NCT06191744)
DESCRIPTION:Obinutuzumab\, phase 3\, Follicular Lymphoma.\nStudy: Study of 
 Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Ora
 l Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activit
 y in Adult Participants With Previously Untreated Follicular Lymphoma\nEst
 imated primary completion: November 2037. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/obinutuzumab#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT06191744
URL:https://assetmemo.bio/drug/obinutuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06191744-3126@assetmemo.bio
DTSTAMP:20261121T005642Z
DTSTART;VALUE=DATE:20371130
DTEND;VALUE=DATE:20371201
SUMMARY:Lenalidomide: Phase 3 readout est. (NCT06191744)
DESCRIPTION:Lenalidomide\, phase 3\, Follicular Lymphoma.\nStudy: Study of 
 Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Ora
 l Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activit
 y in Adult Participants With Previously Untreated Follicular Lymphoma\nEst
 imated primary completion: November 2037. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/lenalidomide#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT06191744
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06191744-4915@assetmemo.bio
DTSTAMP:20261121T005642Z
DTSTART;VALUE=DATE:20371130
DTEND;VALUE=DATE:20371201
SUMMARY:Rituxan (Rituximab): Phase 3 readout est. (NCT06191744)
DESCRIPTION:Rituxan (Rituximab)\, phase 3\, Follicular Lymphoma.\nStudy: St
 udy of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab 
 and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease 
 Activity in Adult Participants With Previously Untreated Follicular Lympho
 ma\nEstimated primary completion: November 2037. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/rituximab#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT06191744
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06191744-10986@assetmemo.bio
DTSTAMP:20261121T005642Z
DTSTART;VALUE=DATE:20371130
DTEND;VALUE=DATE:20371201
SUMMARY:Epcoritamab: Phase 3 readout est. (NCT06191744)
DESCRIPTION:Epcoritamab\, phase 3\, Follicular Lymphoma.\nStudy: Study of S
 ubcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral
  Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity
  in Adult Participants With Previously Untreated Follicular Lymphoma\nEsti
 mated primary completion: November 2037. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/epcoritamab#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT06191744
URL:https://assetmemo.bio/drug/epcoritamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
